<?php
	// $pageTitle = "Page Title";
	// $description = "Description text here";
	// $keywords = "Keywords here";
	// $activePage = "home";
	
	include("includes/header.php");
?>
    <div class="content">
        <section id="efficacy-page-banner" class="efficacy-page-banner" style="margin-top:-16px;">
             <div class="col-xs-12 col-sm-6 col-md-8 col-lg-8">
                            </div>
            <img src="assets/images/efficacy.jpg" alt="" class="img-responsive efficacy-banner" style="position: relative;bottom:-1px;width: 100%;"> 
            <div class="image-caption">
                <div class="container">
                    <div class="row">
                        <div class="col-sm-7 col-md-7 col-lg-7">
                           
                            
                        </div>
                    </div>
             
                </div>
            </div>
        </section>
		
		 <section id="our-services" class="our-services"style="position: relative; bottom:-1px; height: 700px;">
                <div class="container">
                    <div class="row">
					  <div class="col-xs-12 col-sm-3 col-md-3 col-lg-3">
					  </div>
                         <section id="efficacy-page-card" class="efficacy-page-card">
                             <div class="top-text">
                                <h3 style="font-weight:600;color:#d40072;margin-left: 266px;line-height: 1.5;">
                                    IGNITE1 + IGNITE4: Primary Efficacy Endpoint <br>
                                    &nbsp;&nbsp;&nbsp;
                 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical Response in micro-ITT at TOC</h3>
                               <!-- <a href=""><h4 style="margin-left: 159px;color:#d40072">SEE OUR LATEST DEVELOPMENTS > </h4></a> -->
                            </div>
            <img src="assets/images/card.png" alt="" class="img-responsive home-card" style="margin-left: 90px;position:relative; bottom: 130px;">
            <div class="image-caption">
                <div class="container">
                    <div class="row">
                        <div class="col-sm-7 col-md-7 col-lg-7">
                           
                            
                        </div>
                    </div>
             
                </div>
            </div>
        </section>
  
                 </div>
                </div>
            </section>
            <section id="our-services" class="our-services"style="position: relative; bottom:75px;    margin-top: 74px;">
                <div class="container">
                    <div class="row">
                      <div class="col-xs-12 col-sm-3 col-md-3 col-lg-3">
                      </div>
                         <section id="efficacy-page-card" class="efficacy-page-card">
                             <div class="top-text" style="position: relative; right: 62px;">
                                <h3 style="font-weight:600;color:#d2006c;margin-left: 266px;">
                                    Clinical Cure Rate at the TOC Visit by Baseline Pathogen 
                                  </h3>
                              
                            </div>
            <img src="assets/images/card1.png" alt="" class="img-responsive home-card1" style="margin-left: 90px;">
            
         <p style="position: relative;
    top: 30px;
    margin-bottom: 80px;
    left: 150px;">
           <sup>a</sup>Comparators include ertapenem and meropenem</p>
            <div class="image-caption">
                <div class="container">
                    <div class="row">
                        <div class="col-sm-7 col-md-7 col-lg-7">
                           
                            
                        </div>
                    </div>
             
                </div>
            </div>
        </section>
        <div class="panel-group" id="accordion" role="tablist" aria-multiselectable="true">

        
                         <div class="col-xs-12 col-sm-3 col-md-1 col-lg-1">
                      </div>
                    </div>
                 </div>
                </div>
            </section>

            <section id="our-services" class="our-services"style="position: relative; bottom:76px;">
                <div class="container">
                    <div class="row">
                      <div class="col-xs-12 col-sm-3 col-md-3 col-lg-3">
                      </div>
                         <section id="efficacy-page-card" class="efficacy-page-card">
                             <div class="col-xs-12 col-sm-6 col-md-9 col-lg-9">
                            <div class="top-text">
                                <h3 style="font-weight:700;color:#580f8b;width: 910px; position: relative;   right:17px;font-size: 25px; font-family: politica;">
                                     CLINICALLY EFFICTIVE AGAINST CHALLENGING RESISTANT BACTERIA<sup> 4</sup>  </h3><br>
                                 <a href=""><h4 style="margin-left: 183px;color:#d40072;font-weight: 700;">Clinical Cure Rate in Enterobacteriaceae </h4></a>    
                                <h4 style="text-align:center;     margin-right:170px;">Pooled data from IGNITE1 and IGNITE4</h4>
                               
                            </div>
                        </div>
            <img src="assets/images/card2.png" alt="" class="img-responsive home-card2" style="margin-left: 150px;">
            <div class="image-caption">
                <div class="container">
                    <div class="row">
                        <div class="col-sm-7 col-md-7 col-lg-7">
                           
                            
                        </div>
                    </div>
             
                </div>
            </div>
        </section>
        <div class="panel-group" id="accordion" role="tablist" aria-multiselectable="true">

        
                         <div class="col-xs-12 col-sm-3 col-md-1 col-lg-1">
                      </div>
                    </div>
                 </div>
                </div>
            </section>

            <!-- <section id="efficacy-page-discover" class="efficacy-page-discover">
             <div class="col-xs-12 col-sm-6 col-md-8 col-lg-8">
                            </div>
            
            <img src="images/discover.jpg" alt="" class="img-responsive efficacy-discover" style="position: relative;bottom: 55px;"> 
            <h3 style="position: relative; bottom: 180px;">XERAVA IS THE FIRST FULLY SYNTHETIC FLUOROCYCLINE <br> ANTIBACTERIAL TO HELP FIGHT RESISTANT PATHOGENS IN cIAI1,5 
                            </h3>
            <div class="image-caption">
                <div class="container">
                    <div class="row">
                        <div class="col-sm-7 col-md-7 col-lg-7">
                           
                            
                        </div>
                    </div>
             
                </div>
            </div>
        </section> -->
         <section>
        <div class="container-fluid" style="background-image: url(assets/images/discover.jpg); background-size:100% ; height:200px;position: relative;
        bottom: 77px; ">
                <h3 style="color:white;text-align:center;margin-top:30px; margin-bottom:20px;font-weight: 700;line-height: 1.5;">XERAVA IS THE FIRST FULLY SYNTHETIC FLUOROCYCLINE <br> ANTIBACTERIAL TO HELP FIGHT RESISTANT PATHOGENS IN cIAI1,5 </h3>
                <button type="button" class="btn btn-danger mybutton btn-sx"><b>DISCOVER THE DIFFERENCE</b></button>
                
        </div>
    </section>
<style>
    .mybutton {
  background:none ;
  color: white;
  border: 1px solid white;
  border-radius: 20px;
  margin-left: 47%;
  


  
}
button.btn.btn-danger.mybutton {
  outline: none;
}
    </style>

        <!--banner ends -->
     <section id="our-department" class="our-department">
                <div class="container">
              
                    <div class="row">
                        <div class="">
                         
                            <div class="tab-content tab-content col-sm-12 col-md-12  no-padding">
                                <div class="tab-pane active" id="CARDIOLOGY">
                                    <div class="tab-image">
                                        
                                    <p  style="font-size:16px;">
                                      CEPH-R, cephalosporin-resistant; cIAI, complicated intra-abdominal infection; ESBL, extended-spectrum beta-lactamase; IV, intravenous; MDR, multidrug-resistant; micro-ITT, microbiologic intent-to-treat; q8h, every 8 hours; q12h, every 12 hours; q24h, every 24 hours; TOC, Test of Cure.   </p>
									   <p style="font-size:16px;"><b>References: 1.</b> XERAVA [prescribing information]. Watertown, MA: Tetraphase Pharmaceuticals, Inc.; 2018. 2. National Institutes of Health. US National Library of Medicine. Efficacy and safety study of eravacycline compared with ertapenem in complicated intra-abdominal infections (IGNITE1). https://clinicaltrials.gov/ct2/show/NCT01844856?term=IGNITE+eravacycline&rank=1. Updated March 21, 2016. Accessed July 26, 2018. 3. US National Library of Medicine. Efficacy and safety study of eravacycline compared with meropenem in complicated intra-abdominal infections (IGNITE4). https://clinicaltrials.gov/ct2/show/NCT02784704?term=IGNITE+eravacycline&rank=2. Accessed July 26, 2018. 4. Ditch K, Newman J, Izmailyan S, Fyfe C, Tsai L. Microbiological efficacy of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including MDR isolates: a pooled analysis from IGNITE1 and IGNITE4, two phase 3 trials of complicated intra-abdominal infection. Poster presented at: ASM Microbe; June 7-11, 2018; Atlanta, GA. P629. 5. Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76:567-588.</p><br><br>
									   
									   <p class="blue" style="margin-top: 130px;">
                                       Indications and Usage </p>
                                
                                    <p>XERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in patients 18 years or older.</p><br>
									<p><u>Limitations of Use</u></p>
									<p>
XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI).</p><br>
<p class="blue">Usage</p>
<p class="">To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p><br>
<p class="blue">Important Safety Information</p>
<p>XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline or to tetracycline-class antibacterial drugs. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA.</p><br>
<p>The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. </p><br>
<p>The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.</p><br>
<p>Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis. </p><br>
<p>The most common adverse reactions observed in clinical trials (incidence â‰¥ 3%) were infusion site reactions (7.7%), nausea (6.5%), and vomiting (3.7%). </p><br>
<p>XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri, and anti-anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA.  Discontinue XERAVA if any of these adverse reactions are suspected.</p><br>
<p><b>To report SUSPECTED ADVERSE REACTIONS, contact Tetraphase Pharmaceuticals Inc., at 1-833-7-XERAVA (1-833-793-7282) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</b></p> 
                                </div>
                           
                          
                            </div>
                        </div>
                        <!-- tab content -->
                    </div>
                </div>
            </section>
    </div>
    <?php
	// $pageTitle = "Page Title";
	// $description = "Description text here";
	// $keywords = "Keywords here";
	// $activePage = "home";
	
	include("includes/footer.php");
?>